Arrowhead Pharmaceuticals (NASDAQ:ARWR) Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT).
The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a
